Risk Evaluation and Mitigation Strategy (REMS) – Impact on Pain Treatment

Risk Evaluation and Mitigation Strategy (REMS) – Impact on Pain Treatment

In July 2012, the US Food and Drug Administration released a risk evaluation and mitigation strategy (REMS) for extended release pain medications. Lynn Webster, MD, president elect of the American Academy of Pain Medicine, discusses how this REMS will affect patients in pain and the physicians who treat them. (July 19, 2012)

Share your thoughts